Deadpool
Did someone say KFC
"May the force be with you"Now why couldn't they have had it on May the 4th....that would add a little extra science fiction
BRN Discussion Ongoing
- Thread starter TechGirl
- Start date
Food4 thought
Regular
Mmm sorry about that chiefThat was a trick question .... the knob is obviously the one actually holding the phone
Fox151
Regular
Would it be fair to say that you are one of the several people who reported the MF article that I posted earlier? To me, it's one of the strongest written articles they've written in a while, and with the BRN/ARM webinar coming up, perhaps they're trying to go hard to get their shorts squared away before BRN / ARM present and their shorts get shit all through them?
This constant reporting / moderating of everything is BS and people need to grow up. None of the countries BRN is being developed by is an authoritarian regime. Freedom of speech, let alone thought, still exist. Moderating the MF because it discusses the purchase / sale of shares is rediculous. Accept there's an alternative point of view, and consider not just the content of the negativity but also their motivations. You can't do that if people are going to get rid of everything that gets posted here.
The recent MF article that I read was just a rehash of the same points they've been making all along. Apart from the SP, there was no "new" information in the article. The article was devoid of any reference to the great strides the company has made over the last 12 months, or the last 5 years for that matter, let alone any analysis of what the possible outcomes of that may be.
That can be attributed to laziness or malice.
Last edited:
Damo4
Regular
Reporting content if you think it violates rules or laws is the correct thing to do, so if it's justified it's what a report function is there for.
I guess I'm not surprised by the vocal hand wringing recently (and early thumbs down voting) of executive and board compensation packages by a loud and vocal minority of shareholders here on the TSE. I presume that a falling stock price and lumpy modest revenue has not warmed some stockholders hearts with respect to pay for perfomance incentives and may be an understatement.
Your concerns seem perfectly reasonable because they represent your personal opinion on this matter. So, have at it and best of luck.
Now my own opinion of some comments with respect to the matters of incentives and compensation is that I originally invested in a small company with a most interesting and unique approach to edge processing, but I remain invested because of my faith in what I perceive to be a strong executive team and board of directors and a clear strategy to future profitability that is being pursued. If I have a problem with incentive or compensation packages I believe I should take it up with the renumeration committee, or the board, or even vote no as others have announced on TSE.
To that point a read of the Governance documents (Investor Relations / Governance / Documents) found on Brainchip website may inform you why the company operates as they do. In 14 pdf's .... it's all there.
That revenue and income results have been slow to materialize jibes reasonably well with two random observations made by partners in the past.
Observation example # 1
Nviso put a video out about a year or so ago where there were two people in the front seat - one driving a car and the other a passenger, both Nviso employees I believe, and one in the back who was asking questions and filming the trip who I don't believe was a company employee. They had Akida tech working on an Nvidia device demonstrating facial features recognition. At the end of this video one the the employees was heard to respond to a question from the guy in the back seat about when might they be producing such technology as an Nviso product and I think one of the employess said 2025.
Observation example # 2
Renee Haas the CEO of ARM Holdings made the rounds about a year + ago on the TV business shows and he clearly stated and I will paraphrase, that it takes about four years to get from product concept and design to actual products being produced and available.
One observation was from a small partner company, and the other from the CEO of a HUGE partner company. However, both timelines are close. That to me is significant.
These two examples help me to better understand the timelines involved in technology design and implementation. Further, because of such timeframe examples I am less exasperated with Brainchips lumpy revenue streams we are seeing and will likey see in the next quarterly report to be released soon which I fully expect my reaction to be a yawn.
Finally, I can't recall precisely what our CEO said at last years AGM but unless he specifically said he wanted to be judged on financial results or financial progress this past year then he has in fact overseen a growing company that has accomplished a lot. Those accomplishments are just not being reflected in an increasing stock price now because the market abhors a vaccuum of ever increasing revenue and income and as noted by Mr. Viana, the board chair, the stock will do what the stock does .... which we can all agree hasn't been pretty recently.
So, as the two observations above demonstrate I for one am seeing a 2024 / 2025 timeframe as being when Brainchips revenue "should" really grow.
If you made it this far.... thanks for listening. Regards, dippY
Above is my opinion only and lacks any semblence to investible advice which to act upon.
Your concerns seem perfectly reasonable because they represent your personal opinion on this matter. So, have at it and best of luck.
Now my own opinion of some comments with respect to the matters of incentives and compensation is that I originally invested in a small company with a most interesting and unique approach to edge processing, but I remain invested because of my faith in what I perceive to be a strong executive team and board of directors and a clear strategy to future profitability that is being pursued. If I have a problem with incentive or compensation packages I believe I should take it up with the renumeration committee, or the board, or even vote no as others have announced on TSE.
To that point a read of the Governance documents (Investor Relations / Governance / Documents) found on Brainchip website may inform you why the company operates as they do. In 14 pdf's .... it's all there.
That revenue and income results have been slow to materialize jibes reasonably well with two random observations made by partners in the past.
Observation example # 1
Nviso put a video out about a year or so ago where there were two people in the front seat - one driving a car and the other a passenger, both Nviso employees I believe, and one in the back who was asking questions and filming the trip who I don't believe was a company employee. They had Akida tech working on an Nvidia device demonstrating facial features recognition. At the end of this video one the the employees was heard to respond to a question from the guy in the back seat about when might they be producing such technology as an Nviso product and I think one of the employess said 2025.
Observation example # 2
Renee Haas the CEO of ARM Holdings made the rounds about a year + ago on the TV business shows and he clearly stated and I will paraphrase, that it takes about four years to get from product concept and design to actual products being produced and available.
One observation was from a small partner company, and the other from the CEO of a HUGE partner company. However, both timelines are close. That to me is significant.
These two examples help me to better understand the timelines involved in technology design and implementation. Further, because of such timeframe examples I am less exasperated with Brainchips lumpy revenue streams we are seeing and will likey see in the next quarterly report to be released soon which I fully expect my reaction to be a yawn.
Finally, I can't recall precisely what our CEO said at last years AGM but unless he specifically said he wanted to be judged on financial results or financial progress this past year then he has in fact overseen a growing company that has accomplished a lot. Those accomplishments are just not being reflected in an increasing stock price now because the market abhors a vaccuum of ever increasing revenue and income and as noted by Mr. Viana, the board chair, the stock will do what the stock does .... which we can all agree hasn't been pretty recently.
So, as the two observations above demonstrate I for one am seeing a 2024 / 2025 timeframe as being when Brainchips revenue "should" really grow.
If you made it this far.... thanks for listening. Regards, dippY
Above is my opinion only and lacks any semblence to investible advice which to act upon.
D
Deleted member 118
Guest
Why do they use may be and not is
this information may be considered inside information
FlipDollar
Never dog the boys
Solid post
I am 98.2% sure this will be us.......DYOR!Should probably start checking out Untether AI......
Untether AI and General Motors to Develop Next-Generation Autonomous Vehicle Perception Systems — Untether AI
With funding from the Government of Ontario through the Ontario Vehicle Innovation Network (OVIN), the project aims to increase autonomous vehicle performance by providing faster and more accurate vision response. TORONTO, Canada – April 28, 2022 – Untether AI , the leader inbit.ly
View attachment 5245
"Arun Iyengar, CEO of Toronto-based tech firm Untethered AI, explains that traditional AI methods are a huge drain on the world’s energy resources.
“Just looking at January, if you look at the number of people that used ChatGPT and the amount of energy it took to serve them, it would be the same amount of energy to fully serve a town of 175,000 people,” he says.
That’s because it’s using methods established as far back as the 1940s by John von Neumann, widely considered the father of modern AI technology, which has powered all computer chips to date.
“Anytime you move data you burn energy. So the more distance you move data, the more power you’re burning to make that happen. And that’s why today’s implementations end up consuming so much power.”
Iyengar’s company, a semiconductor startup, has created a first-of-its-kind chip that aims to dramatically reduce AI’s energy use.
“We are basically putting the processing and the memory right next to each other. So the data movement is now contained in a very,
very short distance … that reduces the power or the energy required to do Artificial Intelligence by a factor of six to 10 times,” he says"
Last edited:
Agree, I think 2024 we should see revenue looking good in the financials.
Markets are forward looking so we should see some SP movement earlier than revenue appears in the Financials.
Dhm
Regular
Just back to the NDA thing, when a company is shown Akida and registers a high degree of excitement yet secrecy about the ‘principle’ of the AI, and decides to do further testing for say a further 3-6 months without any contract signed, yet for whatever reason subsequently walks away, would this company be part of the 100 NDA’s? I’m guessing that we as shareholders aren’t privy to these situations.
Another part of my questioning is, do NDAs come and go and fall away quite regularly in the world of secrecy?
Another part of my questioning is, do NDAs come and go and fall away quite regularly in the world of secrecy?
Food4 thought
Regular
That why I have had a five year plan,
I am about 1/2 way through it and will consider any actions at the end of the 5 years, hold or sell
Food4 thought
Regular
Well given the fact that this forum is about BrainChip let’s just talk about that.
When I invested in Brn originally I knew it would be a long time to get things happening, to have produced and have product on the shelves.
We are not selling fast food
It’s no McDonald’s
Look at any tech firm go and do research on how long their journey have taken them to get traction in the market place.
But with world events that have happened over the last 3 years, that has slowed the wheels down considerably.
So I don’t think we will see much happen before mid 2024 but then it should go ballistic,if everything falls our way.
I see June this year as the start of the slow gathering of open information and increased sales thanks to Mercedes
Then others will start to revel them selves Dell will be coming out soon
Have faith
Hold tight
God speed
Rise from the ashes
Regular
Yeah but my question was if something drastically changed let's just say the future chips totally failed which would turn this stock worthless. You'd still hold for the 5 year plan? And obviously I'm not saying that will happen but I've had the x amount of years plan before and failed miserably by ignoring major stuff ups. Never again will I ignore and blindly stick to a plan
Last edited:
This news article only a few hours old is an excellent read, check it out....pity they didn't actually interview a real
neuroscientist who's actually in the real world, as in, the commercial sense, not from academia, never-the-less it's
still a nice article.
www.9news.com.au
Texta
neuroscientist who's actually in the real world, as in, the commercial sense, not from academia, never-the-less it's
still a nice article.
Will AI ever reach human-level intelligence? Five experts weigh in
There's no doubt AI systems appear to be "intelligent" to some extent. But could they ever be as intelligen...
Texta
D
Deleted member 118
Guest
Well if it does as I’ve a 7 year plan on retiring when Im 60 I’ll guess i will be living in a
TechGirl
Founding Member
Interesting know labs have proof of principle with edge impulse
SEATTLE – April 21, 2023 –Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of a proof-of-principle study titled, “Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions – Implications for Non-Invasive Physiologic Monitoring,” conducted in collaboration with Mayo Clinic. Know Labs will present the results of the study at the American Physiological Society (APS) Summit, which is being held on April 20-23 in Long Beach, California. The study demonstrates the accuracy of Know Labs’ proprietary Bio-RFID™ sensor in quantifying different analytes in vitro, proving a 100% accuracy rate in these tests. The full study is currently undergoing the peer-review publishing process.
Know Labs’ technology platform, Bio-RFID, uses electromagnetic energy in the form of radio waves to non-invasively capture molecular signatures, which can be converted into physiologically meaningful information and insights. While the technology is proven to accurately measure several analytes inside and outside the body, the first application of this technology is aimed at non-invasive glucose monitoring.
“Proof-of-principle studies are critical in demonstrating Bio-RFID’s accuracy for non-invasive methods of medical diagnostics. This was an essential step toward achieving our goal of delivering the first FDA-cleared, truly non-invasive glucose monitoring device to the market,” said Ron Erickson, CEO and Chairman at Know Labs. “To put this into real-world context: imagine being able to continuously and accurately measure different aspects of your health on a molecular level using a pocket-sized (or smaller) sensor instead of a finger prick or a CGM probe.”
Conducted at Mayo Clinic in Rochester, MN in March of 2021, the study included five experiments designed to demonstrate the ability of the Bio-RFID sensor to non-invasively quantify concentrations of solutions using a randomized double-blind trial design, as proxies for biochemical solutions. Solutions including water in isopropyl alcohol, sodium chloride in water, and commercial bleach in water were tested. Data were collected using the Bio-RFID sensor, which generates radio frequency signals and measures received power through an antenna array. The sensor sweeps across the 1500 Megahertz (MHz) - 3000 MHz range at 0.2 MHz intervals, collecting values at 7501 frequencies.
“Market pressures like rising healthcare costs and the rapid increase in remote patient monitoring and care delivery are driving the need for affordable, accurate and non-invasive continuous measures of blood analytes,” said James “Andy” Anderson, M.D., Chief Medical Officer at Know Labs. “What we are describing here is truly ground-breaking. This novel application of the Bio-RFID technology to accurately detect and quantify specific molecules in liquid provides strong support for non-invasive monitoring of physiologically and medically relevant analytes in the human body.”
For each of the five experiments, 100% of solutions in the test data were correctly identified. The Bio-RFID technology was able to detect concentrations as low as 2000 parts per million (ppm) – which is equivalent to accurately measuring the difference of 0.7ml of water dropped into a 12oz can of soda – with evidence suggesting the ability to detect much smaller concentration differences. These in vitro findings provide proof-of-principle, strongly supporting the application of the technology for further non-invasive, physiologic and medical monitoring.
This proof-of-principle study is part of a series of studies that Know Labs is conducting as the company prioritizes external validation of its Bio-RFID technology in detecting and measuring glucose and other analytes in the body non-invasively at high levels of accuracy.
The study abstract and APS Summit Poster can be viewed at www.knowlabs.co. The full manuscript will be published following peer review.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a non-invasive glucose monitor. It will provide the user with real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.
Know Labs Demonstrates Accuracy of Non-Invasive, Bio-RFID Technology with Proof-of-Principle Study
SEATTLE – April 21, 2023 –Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of a proof-of-principle study titled, “Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions – Implications for Non-Invasive Physiologic Monitoring,” conducted in collaboration with Mayo Clinic. Know Labs will present the results of the study at the American Physiological Society (APS) Summit, which is being held on April 20-23 in Long Beach, California. The study demonstrates the accuracy of Know Labs’ proprietary Bio-RFID™ sensor in quantifying different analytes in vitro, proving a 100% accuracy rate in these tests. The full study is currently undergoing the peer-review publishing process.
Know Labs’ technology platform, Bio-RFID, uses electromagnetic energy in the form of radio waves to non-invasively capture molecular signatures, which can be converted into physiologically meaningful information and insights. While the technology is proven to accurately measure several analytes inside and outside the body, the first application of this technology is aimed at non-invasive glucose monitoring.
“Proof-of-principle studies are critical in demonstrating Bio-RFID’s accuracy for non-invasive methods of medical diagnostics. This was an essential step toward achieving our goal of delivering the first FDA-cleared, truly non-invasive glucose monitoring device to the market,” said Ron Erickson, CEO and Chairman at Know Labs. “To put this into real-world context: imagine being able to continuously and accurately measure different aspects of your health on a molecular level using a pocket-sized (or smaller) sensor instead of a finger prick or a CGM probe.”
Conducted at Mayo Clinic in Rochester, MN in March of 2021, the study included five experiments designed to demonstrate the ability of the Bio-RFID sensor to non-invasively quantify concentrations of solutions using a randomized double-blind trial design, as proxies for biochemical solutions. Solutions including water in isopropyl alcohol, sodium chloride in water, and commercial bleach in water were tested. Data were collected using the Bio-RFID sensor, which generates radio frequency signals and measures received power through an antenna array. The sensor sweeps across the 1500 Megahertz (MHz) - 3000 MHz range at 0.2 MHz intervals, collecting values at 7501 frequencies.
“Market pressures like rising healthcare costs and the rapid increase in remote patient monitoring and care delivery are driving the need for affordable, accurate and non-invasive continuous measures of blood analytes,” said James “Andy” Anderson, M.D., Chief Medical Officer at Know Labs. “What we are describing here is truly ground-breaking. This novel application of the Bio-RFID technology to accurately detect and quantify specific molecules in liquid provides strong support for non-invasive monitoring of physiologically and medically relevant analytes in the human body.”
For each of the five experiments, 100% of solutions in the test data were correctly identified. The Bio-RFID technology was able to detect concentrations as low as 2000 parts per million (ppm) – which is equivalent to accurately measuring the difference of 0.7ml of water dropped into a 12oz can of soda – with evidence suggesting the ability to detect much smaller concentration differences. These in vitro findings provide proof-of-principle, strongly supporting the application of the technology for further non-invasive, physiologic and medical monitoring.
This proof-of-principle study is part of a series of studies that Know Labs is conducting as the company prioritizes external validation of its Bio-RFID technology in detecting and measuring glucose and other analytes in the body non-invasively at high levels of accuracy.
The study abstract and APS Summit Poster can be viewed at www.knowlabs.co. The full manuscript will be published following peer review.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a non-invasive glucose monitor. It will provide the user with real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.
D
Deleted member 1269
Guest
@dippY22, I want BrainChip to be as successful as every other shareholder, we all want the same thing.
But just a cut and paste from last years AGM -
Im my opinion, when the CEO is taking about but being judged on results specifically around commercialisation, this means financial results to me.
Similar threads
